Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 3 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 3 5 W ELECTROLYTES.
EPANOVA vs TRAVASOL 3.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids (3.5% crystalline amino acids) and electrolytes for protein synthesis and maintenance of electrolyte balance in patients unable to meet nutritional needs enterally. The amino acids serve as substrates for protein synthesis, while electrolytes support cellular function and acid-base balance.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution